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Objective: HIV cohorts are an important source of clinical data for informing public
health policies and programmes. However, the generalizability of cohort findings to the
wider population of people diagnosed with HIV in each country remains unclear. In this
work, we assessed the representativeness of six large national HIV cohorts within
Europe.
Design and methods: Individual-level cohort data were provided from national
cohorts in France, Germany, Greece, Italy, Spain and the United Kingdom. Analysis
focused on new HIV diagnoses reported to The European Surveillance System (TESSy)
during three time periods (2000–2004, 2005–2009 and 2010–2013), to allow for
temporal changes. Cohort and TESSy records were matched and compared by age,
sex, transmission mode, region of origin and CD4þ cell count at diagnosis. The
probability of being included in each cohort given demographic characteristics was
estimated and used to generate weights inversely proportional to the probability of
being included.
Results: Participating cohorts were generally representative of the national HIV-diag-
nosed population submitted to TESSy. However, people who inject drugs, those born in
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a country other than that reporting the data, those with low CD4þ cell counts at
diagnosis, and those more than 55 years were generally underrepresented in the cohorts
examined.
Conclusion: These European cohorts capture a representative sample of the HIV-
diagnosed populations in each country; however some groups may be underrepre-
sented. Copyright  2018 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
HIV infection continues to be of major public health
importance worldwide, notably because significant
numbers of new infections and premature deaths
continue to occur [1]. In the era of test and treat
approaches and of biomedical prevention [2], the
development and assessment of effective public health
responses requires the monitoring of not only new
diagnoses and routes of transmission, but also other key
markers including linkage to care, treatment uptake and
viral suppression.
HIV surveillance in Europe is carried out by the
European Centre for Disease Prevention and Control
(ECDC) and the WHO Regional Office for Europe.
HIV cases reported annually by European Union
Member States to The European Surveillance System
(TESSy), hosted at ECDC, remain the best estimate of the
number of people diagnosed with HIV, although
underreporting does occur in some Member States.
Although the demographic data collected by TESSy
provides important information for monitoring, data on
clinical indicators are often lacking. EuroCoord was a
Network of Excellence established by several of the
largest HIV cohorts and collaborations within Europe –
as part of this collaborative effort, EuroCoord supported
the development of a combined dataset including
individual demographic data and clinical indicators for
almost 300 000 HIV-positive adults and children [3].
HIV cohorts are an important source of data for
informing policy. However, cohorts may systematically
exclude specific groups of individuals, those less likely to
access care, such as people who inject drugs (PWID) [4–
6]. The representativeness of each cohort is usually
assessed by comparing the characteristics of cohort
participants to those of corresponding reference popula-
tions [7–10]. Several methods to account for selection
bias have been proposed [11–13].
The aim of the present work was to assess the
representativeness of several large cohorts of HIV-positive
adult individuals followed within EuroCoord by com-
paring their characteristics with those diagnosed from the
same countries as submitted to TESSy. These findings can
inform our understanding of whether, and in which
settings and population groups, results based on cohort
data can be generalized to the wider population, allowing
ECDC, European Union Member States, and the
European Commission to confidently use cohort data
to provide guidance on issues of public health importance
with regard to HIV infection.
Methods
Seven cohorts within EuroCoord that do not form the
basis of their respective national surveillance systems were
included in analyses: the French Hospitals Database on
HIV ANRS CO4 and Aquitaine ANRS CO3 from
France [14,15], Clinical Surveillance of HIV Disease
(ClinSurv) from Germany [16], Athens Multicentre
AIDS Cohort Study (AMACS) from Greece, Italian
Cohort Naı¨ve Antiretrovirals (ICONA) from Italy [17],
Cohort of the Spanish HIV Research Network (CoRIS)
from Spain, and the UK Collaborative HIV Cohort (UK
CHIC) from the United Kingdom [18].
TESSy data of individuals diagnosed up to 2013 and
reported up to 2015 in these six countries were provided
by ECDC under agreement for data confidentiality.
Anonymized data with variables on age, sex, transmission
mode, country/region of origin, year of diagnosis and
CD4þ cell counts at diagnosis were included. Individual
cohort data on the same variables were provided from
each participating country. All participating cohorts had
approval from relevant country authorities.
Statistical analysis
TESSy data were considered as the gold standard against
which the characteristics of cohort participants were
compared. Analyses focused on HIV cases diagnosed
during the time periods 2000–2004, 2005–2009 and
2010–2013 to account for changes in individual
characteristics over time. Each country and time period
was analysed separately.
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To avoid confusion due to different percentages of
missing data in TESSy and the cohorts, multivariate
imputation by chained equations was applied before
analysis (see Appendix, http://links.lww.com/QAD/
B370) [19]. Transmission mode was categorized as:
MSM, PWID and ‘other’, which mainly included those
reportedly infected through heterosexual contact.
Region of origin was categorized as: reporting country,
other European (nonreporting) country/Australia/North
America and Africa/Asia/Latin America. Age was
categorized as 15–24.9, 25–34.9, 35–44.9, 45–54.9
and at least 55 years; and CD4þ cell counts as less than
200, 200–349, 350–499 and at least 500 cells/ml. Region
of origin was not adequately recorded in ClinSurv,
whereas ethnicity instead of origin was recorded in the
UK CHIC Study and thus it was not analysed in these
countries. In ICONA, participants from Italy were
recorded as Europeans, and thus the region of origin
could only be categorized in two groups. CD4þ cell
counts were not reported to TESSy from Germany and
for France were only reported from 2008 onwards.
TESSy and cohort datasets from each country were
merged by a pseudo-id created by combining each
individual covariate pattern with a unique within-
covariate pattern serial number. The distributions of
individual characteristics in the two datasets were
compared. An indicator of whether a diagnosed
individual reported to TESSy was included in the cohort
was generated. Multivariable logistic regression models
were fitted to estimate the probability of diagnosed
individuals being included in the cohort given their
characteristics and stabilized weights inversely propor-
tional to this probability were generated [11–13].
Inference was based on the median stabilized weights for
the levels of the studied covariates, pooled over all periods
and other covariates, along with the corresponding
interquartile range (IQR); underrepresentation required
that the entire IQR was greater than 1.
Results
In total, 235 437 individuals reported to TESSy and
96 768 cohort participants of known sex, diagnosed after
2000 and during the periods covered by both surveillance
and cohorts, were included in the analyses.
In general, the cohorts captured the main characteristics
of the HIV-diagnosed individuals in the corresponding
countries (Table 1). Main trends over time observed in
TESSy were also seen in the cohorts. However, specific
subgroups were underrepresented (Fig. 1). PWID, those
born in another country, those with low CD4þ cell
counts at diagnosis, older individuals and women were, in
general, underrepresented in the cohorts, but in different
degrees across different countries (Fig. 1). PWID were
underrepresented in France, Greece, Spain and the
United Kingdom. In Germany, this finding held only for
the 2005–2009 period. In Italy, Spain and the United
Kingdom, individuals reporting other transmission mode
were underrepresented; in France and Greece individuals
originated from other than the reporting country and in
Spain those originated from another (nonreporting)
European country were also underrepresented; individu-
als who were older than 55 years were underrepresented
in Italy, Spain, the United Kingdom and, to some extent,
in Greece. Women were also slightly underrepresented in
most countries including Italy, Spain and the United
Kingdom, whereas in Greece, women were underrepre-
sented only in the 2005–2009 period.
Although the degree of underrepresentation or overrep-
resentation was quite low when we considered each
variable separately, it varied substantially when we
considered the degree of representation by covariate
patterns (i.e. combining all variables). In France, PWID
originated from outside the country were highly
underrepresented (stabilized weights: 1.8–13.1), as were
MSM originated from Africa, Asia or Latin America
(stabilized weights: 1.2–4.6). Similarly, in Greece, PWID
originated from other European countries were substan-
tially underrepresented (stabilized weights: 1.6–4.9). In
Spain, PWID originated from other countries were also
underrepresented (stabilized weights: 1.5–3.4).
Application of inclusion weights efficiently compensated
for observed imbalances and reproduced the structure of
the corresponding diagnosed population (Appendix, Fig.
A1, http://links.lww.com/QAD/B370).
Discussion
This is the first effort to assess the representativeness of
European HIV cohorts within EuroCoord compared
with the wider population of HIV-diagnosed individuals
reported to TESSy. Our findings suggest that, whilst
cohort participants are a fairly representative sample of
HIV-diagnosed individuals, some groups remain under-
represented or overrepresented within these cohorts.
All participating cohorts, other than CoRIS in which
participants are also recruited from an STI clinic, are HIV
clinic-based. Thus, differences between cohorts and
TESSy data may reflect differences between individuals
who are and are not linked to care. PWID tended to be
underrepresented in all cohorts and time periods, except
in ICONA. Impaired access to care and retention in care
for PWID is a global challenge [6,20,21]. Older
individuals also tended to be underrepresented in some
cohorts. Results from previous studies are conflicting,
reporting either higher or lower probability of inclusion
HIV cohorts’ representativeness Vourli et al. 135







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































for older individuals [5,22]. However, it has been
reported previously that older age is significantly
associated with late diagnosis [23]. As previously
described [5], women were also slightly underrepresented
in most cohorts. In accordance with previous studies that
report suboptimal access to care among migrants, there
were indications that migrants were underrepresented
[24,25]. Individuals with low CD4þ cell counts were less
likely to be included in most cohorts, possibly because
they may die shortly after their diagnosis, or because they
often start combined antiretroviral treatment (cART)
immediately and are perhaps excluded from cohorts
recruiting cART-naı¨ve individuals (e.g. ICONA,
CoRIS). Underrepresentation of individuals with a low
CD4þ cell count in cohorts has also been reported [5].
In this work, TESSy data were considered the gold
standard with which cohort data were compared.
However, surveillance data also have limitations. Changes
over timewere taken into account by analysing each study
period separately. To account for reporting delays, we
analysed data up to 2013, whereas the average delays in
the analysed countries are less than 6 months [26].
Surveillance data included in TESSy may underestimate
the number of people diagnosed with HIV in some
countries, because of underreporting (as in France,
underreporting was estimated at 29.6% for 2010–2013 in
France). Additional limitations include a lack of data on
migrant status as well as misclassified and/or missing data
that are more likely to occur in surveillance settings than
in cohorts. Thus, differences between cohort and
surveillance data may be due to the different conditions
under which data collection is performed by cohorts and
surveillance systems.
The observed differences may also reflect delayed
enrolment into the cohorts. In cases of recent epidemics
in specific groups, enhanced linkage to care is essential so
that these newly infected individuals are promptly
provided access to ART and clinical follow-up and,
where relevant, included in HIV cohorts.
In summary, our findings indicate that the main European
cohorts capture a representative sample of the HIV-







































































































































































Fig. 1. Distribution of the stabilizedweights assigned to cohorts’ participants, pooled over all time periods by transmissionmode
(MSM; people who inject drugs; other: mainly those reporting heterosexual contact as the source of infection), age group, region
of origin, CD4R cell count category and sex. Region of origin Other-1 corresponds to migrants originating from other European
countries, North America and Australia and other-2 tomigrants originating fromAfrica, Asia and Latin America.Weights regarding
the CD4þ cell counts in France concern only the 2008–2013 period.
diagnosed population. Nevertheless, the sample of
individuals participating in HIV cohorts within Euro-
Coord may differ systematically from the population of
HIV-diagnosed individuals reported to ECDC through
TESSy. Given that vulnerable patients tend to be
underrepresented, estimation of public health indices
based on cohort data could lead to overoptimistic
conclusions. Provided that cohorts are able to capture
data on all characteristics associated with inclusion into
the cohort, weighted analyses are likely to provide more
unbiased estimates of public health-indices [12,13].
Supplementing surveillance data with annual updates of
public health relevance such as treatment uptake and viral
suppression should be the gold standard of HIV
surveillance. This information can be provided from
existing clinical cohorts and should ideally be expanded to
all patients accessing HIV care in a given country.
Therefore, the results of this project could be used to
more effectively triangulate HIV surveillance and cohort
data for public health action.
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